Aytu Biopharma chief business officer buys $24,999 in stock

DENVER—Jarrett Disbrow, the Chief Business Officer of Aytu Biopharma, Inc. (NASDAQ:AYTU), recently acquired shares of the company’s common stock, according to a filing with the Securities and Exchange Commission. On June 9, Disbrow purchased 16,666 shares at a price of $1.50 per share, amounting to a total transaction value of $24,999.

Following this transaction, Disbrow’s total direct ownership stands at 29,462 shares. This purchase was made as part of Aytu Biopharma’s registered offering, detailed in their Registration Statement on Form S-1, as amended and filed on June 2, 2025. According to InvestingPro analysis, analysts have set an $8.00 price target for the stock, suggesting significant upside potential. Get access to 13 more exclusive ProTips and comprehensive analysis with an InvestingPro subscription.

The transaction reflects Disbrow’s continued involvement and investment in Aytu Biopharma, a company that underwent a 1-to-20 reverse stock split on January 6, 2023. The company currently trades at a low revenue multiple, and InvestingPro data indicates net income is expected to grow this year.

In other recent news, Aytu BioPharma has reported a significant financial performance for Q3 FY2025, with net revenue reaching $18.5 million, marking a 32% increase year-over-year. This growth was primarily driven by the company’s ADHD portfolio, which saw a 25% rise in revenue to $15.4 million, and the pediatric portfolio, which surged 77% to contribute $3.1 million. The company also achieved a net income of $4 million, a notable turnaround from a previous loss, and maintained a gross margin of 69%. Aytu BioPharma is actively exploring strategic acquisitions to enhance its existing product lines in the CNS and pediatric therapeutic areas. In other developments, the company has secured exclusive rights to commercialize EXXUA™, a new FDA-approved antidepressant for major depressive disorder, in the U.S. market. This agreement with Fabre-Kramer Pharmaceuticals includes upfront payments, royalties, and performance-based milestone payments. Aytu BioPharma plans to launch EXXUA in the fourth quarter of 2025, with strong backing from key investors like Nantahala Capital Management.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.